Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer

WM Grady - Advances in cancer research, 2021 - Elsevier
Colorectal cancer is a leading cause of cancer related deaths worldwide. One of the
hallmarks of cancer and a fundamental trait of virtually all gastrointestinal cancers is …

Overview on clinical relevance of intra-tumor heterogeneity

G Stanta, S Bonin - Frontiers in medicine, 2018 - frontiersin.org
Today, clinical evaluation of tumor heterogeneity is an emergent issue to improve clinical
oncology. In particular, intra-tumor heterogeneity (ITH) is closely related to cancer …

Machine learning and network analyses reveal disease subtypes of pancreatic cancer and their molecular characteristics

M Sinkala, N Mulder, D Martin - Scientific reports, 2020 - nature.com
Given that the biological processes governing the oncogenesis of pancreatic cancers could
present useful therapeutic targets, there is a pressing need to molecularly distinguish …

Epigenetic alterations in pancreatic cancer metastasis

SS Wang, J Xu, KY Ji, CI Hwang - Biomolecules, 2021 - mdpi.com
Pancreatic cancer is the third leading cause of cancer-related deaths in the United States.
Pancreatic ductal adenocarcinoma (PDA) is the most common (90%) and aggressive type of …

ELMER v. 2: an R/Bioconductor package to reconstruct gene regulatory networks from DNA methylation and transcriptome profiles

TC Silva, SG Coetzee, N Gull, L Yao, DJ Hazelett… - …, 2019 - academic.oup.com
Motivation DNA methylation has been used to identify functional changes at transcriptional
enhancers and other cis-regulatory modules (CRMs) in tumors and other disease tissues …

Survival analysis of multi-omics data identifies potential prognostic markers of pancreatic ductal adenocarcinoma

NK Mishra, S Southekal, C Guda - Frontiers in genetics, 2019 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is the most common and among the deadliest of
pancreatic cancers. Its 5-year survival is only∼ 8%. Pancreatic cancers are a …

DNA-methylation signature accurately differentiates pancreatic cancer from chronic pancreatitis in tissue and plasma

Y Wu, I Seufert, FN Al-Shaheri, R Kurilov, AS Bauer… - Gut, 2023 - gut.bmj.com
Objective Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Differentiation
from chronic pancreatitis (CP) is currently inaccurate in about one-third of cases …

MYEOV increases HES1 expression and promotes pancreatic cancer progression by enhancing SOX9 transactivity

E Liang, Y Lu, Y Shi, Q Zhou, F Zhi - Oncogene, 2020 - nature.com
Emerging evidence indicates that myeloma overexpressed (MYEOV) is an oncogene and
plays crucial roles in multiple human cancers. However, its roles in the development of …

Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model

LA Torre-Healy, RR Kawalerski, K Oh… - Communications …, 2023 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease for which potent
therapies have limited efficacy. Several studies have described the transcriptomic landscape …

The emerging roles of ATP-dependent chromatin remodeling complexes in pancreatic cancer

N Hasan, N Ahuja - Cancers, 2019 - mdpi.com
Pancreatic cancer is an aggressive cancer with low survival rates. Genetic and epigenetic
dysregulation has been associated with the initiation and progression of pancreatic tumors …